Heterocyclic compounds and their pharmaceutical formulation
US5091395A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 4, 1988 |
| Grant date | Feb 25, 1992 |
| Priority date | — |
| Expiry date | Nov 4, 2008 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D211/90
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds are described of the formula ##STR1## wherein R.sub.1 and R.sub.4 independently represent a C.sub.1-4 alkyl group; PA1 R.sub.2 and R.sub.3 independently represent a C.sub.1-6 straight or branched alkyl chain or alkoxy group; PA1 R.sub.5 represents a straight or branched chain C.sub.1-13 alkyl group or a C.sub.5-8 cycloalkyl group which may be substituted by a C.sub.1-3 alkyl substituent; PA1 R.sub.6 represents a halogen atom or a straight or branched C.sub.1-3 alkyl group. The compounds represented by formula (I) reduce intracellular calcium ion concentration by limiting transmembranal calcium ion reflux and thus may be useful for the treatment of cardiovascular disorders such as hypertension.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.